Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding an increase in their ordinary shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The material change reported is an increase in share interests for specific directors and their connected persons. This increase resulted from the re-investment of dividends paid to shareholders on July 7, 2011. The transaction price was 1,369.51 pence per ordinary share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of shareholding changes in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Type: Increase in shareholdings via dividend re-investment.
- Transaction Date: July 7, 2011 (dividend payment); July 11, 2011 (notification).
- Share Price: 1,369.51 pence per ordinary share.
- Directors Involved: Mr. A.P. Witty (49 shares), Dr. D. Pulman (322 shares), and Mrs. V.A. Whyte (no direct increase).
- Connected Persons Involved: Mrs. C.M. Witty (2,049 shares), Mrs. C.R. Pulman (66 shares), and Mr. I.W. Whyte (62 shares).